Genetic Deletion or Pharmacological Inhibition of Cyclooxygenase-2 Reduces Blood-Brain Barrier Damage in Experimental Ischemic Stroke

Changjun Yang¹, Yi Yang², Kelly M. DeMars¹, Gary A. Rosenberg² and Eduardo Candelario-Jalil¹*

¹Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, United States, ²Department of Neurology, Center for Memory and Aging, University of New Mexico Health Sciences Center, Albuquerque, NM, United States

Cyclooxygenase (COX)-2 and matrix metalloproteinase (MMP)-9 are two crucial mediators contributing to blood-brain barrier (BBB) damage during cerebral ischemia. However, it is not known whether MMP-9 activation is involved in COX-2-mediated BBB disruption in ischemic stroke. In this study, we hypothesized that genetic deletion or pharmacological inhibition of COX-2 reduces BBB damage by reducing MMP-9 activity in a mouse model of ischemic stroke. Male COX-2 knockout (COX-2−/−) and wild-type (WT) mice were subjected to 60 min of middle cerebral artery occlusion (MCAO) followed by 24 h of reperfusion. Genetic deletion of COX-2 or post-ischemic treatment with CAY10404, a highly selective COX-2 inhibitor, significantly reduced BBB damage and hemorrhagic transformation, as assessed by immunoglobulin G (IgG) extravasation and brain hemoglobin (Hb) levels, respectively. Immunoblotting analysis showed that tight junction proteins (TJPs) zonula occludens (ZO)-1 and occludin as well as junctional adhesion molecule-A (JAM-A) and the basal lamina protein collagen IV were dramatically reduced in the ischemic brain. Stroke-induced loss of these BBB structural proteins was significantly attenuated in COX-2−/− mice. Similarly, stroke-induced loss of ZO-1 and occludin was significantly attenuated by CAY10404 treatment. Ischemia-induced increase in MMP-9 protein levels in the ipsilateral cerebral cortex was significantly reduced in COX-2−/− mice. Stroke induced a dramatic increase in MMP-9 enzymatic activity in the ischemic cortex, which was markedly reduced by COX-2 gene deficiency or pharmacological inhibition with CAY10404. Levels of myeloperoxidase (MPO, an indicator of neutrophil infiltration into the brain parenchyma), neutrophil elastase (NE), and lipocalin-2 (LCN2, also known as neutrophil gelatinase-associated lipocalin), measured by western blot and specific ELISA kits, respectively, were markedly increased in the ischemic brain. Increased levels of markers for neutrophil infiltration were significantly reduced in COX-2−/− mice compared with WT controls following stroke. Altogether, neurovascular protective effects of COX-2 blockade are associated with reduced BBB damage, MMP-9 expression/activity and neutrophil infiltration. Our study shows for the first time that MMP-9 is an important downstream effector contributing to...
COX-2-mediated neurovascular damage in ischemic stroke. Targeting the COX-2/MMP-9 pathway could represent a promising strategy to reduce neuroinflammatory events in order to preserve the BBB integrity and ameliorate ischemic stroke injury.

**Keywords:** ischemic stroke, blood-brain barrier, cyclooxygenase-2, matrix metalloproteinase-9, tight junction proteins

## INTRODUCTION

Prostaglandin-endoperoxide synthases (PTGS), also known as cyclooxygenases (COXs), are key players in inflammation, and are targets of the widely used non-steroidal anti-inflammatory drugs (NSAIDs) (1). COX exists in three forms: COX-1,−2, and−3, where COX-1 and COX-3 (a splice variant of COX-1) are encoded by the same PTGS1 gene, and COX-2 is encoded by the PTGS2 gene (1). COX-1 is constitutively expressed in most tissues and largely contributes to normal physiological functions. COX-2 is an inducible enzyme that is mostly associated with pathophysiological functions in response to proinflammatory stimuli or growth factors (1), whereas COX-3 is not functional in humans (2).

COX-2 inhibition is an attractive pharmacological target since the metabolism of arachidonic acid (AA) through the COX pathway produces large amounts of proinflammatory prostanoids, such as prostaglandin E2 (PGE2), which are key inflammatory mediators (3, 4). In ischemic rat brain, a dramatic increase in COX-2 expression has been reported starting at 30 min and lasting up to 15 days after stroke (5–8). Previous findings from our group and others have demonstrated that pharmacological inhibition of COX-2 confers neuroprotection in ischemic brain injury (9–14). COX-2 knockout (COX-2−/−) mice display a dramatic reduction in the susceptibility to excitotoxicity and ischemic brain injury (15, 16), whereas neuronal overexpression of COX-2 increases infarct volume associated with a dramatic increase in PGE2 levels in the ischemic brain (17). The detrimental effect of COX-2 after cerebral ischemia is attributed to the production of PGE2 rather than to the generation of oxidative stress (18). Similarly, we previously found that the increase in PGE2 formation in the ischemic cortex correlates with the evolution of cerebral infarct in this brain region, and the accumulation of PGE2 in the ischemic cerebral cortex paralleled the substantial increase in blood-brain barrier (BBB) breakdown and leukocyte infiltration (12). These findings are in line with a previous report showing that PGE2 produces a marked BBB breakdown when administered intracerebrally in rats (19).

There is increasing evidence indicating that COX-2 derived PGE2, matrix metalloproteinase (MMP)-9 production and BBB disruption are important components of neuronal death in the ischemic penumbra, a potentially salvageable tissue surrounding the infarct core (6, 17, 20, 21). Active MMP-9 degrades the basal lamina around blood vessels and vascular endothelial tight junction proteins (TJPs), leading to disruption of the BBB (22–24). This opening of the BBB is associated with vasogenic edema and infiltration of polymorphonuclear leukocytes, which exacerbate brain injury. In non-neural cell types, such as tumor cells, COX-2-derived PGE2 increases MMP-9 expression and activity. It has been demonstrated that tumor cells invasion or metastasis are dramatically reduced by COX-2 inhibitors, and this effect is mediated by a significant reduction in PGE2-mediated MMP-9 expression/activity (25–28). However, it is not known whether MMP-9 activation is involved in COX-2-mediated BBB disruption in ischemic stroke.

In this study, we hypothesized that genetic deletion or pharmacological inhibition of COX-2 reduces BBB damage by reducing MMP-9 activity in a mouse model of ischemic stroke. We found that gene deficiency of COX-2 or post-ischemic treatment with the COX-2 inhibitor, CAY10404, significantly reduced BBB damage and hemorrhagic transformation following transient focal cerebral ischemia, and these neurovascular protective effects were associated with a significant decrease in MMP-9 activity, reduced neutrophil infiltration, and a preservation of structural proteins composing the neurovascular unit.

## METHODS

### Animals

All animal procedures were approved by the University of Florida Institutional Animal Care and Use Committee (protocol # 201607934) and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals, the ARRIVE guidelines (https://www.nc3rs.org.uk/arrive-guidelines). Mice were housed five per cage with free access to food and water in a temperature- and humidity-controlled environment with a 12-h light/dark cycle. All mice were acclimated to our animal facility for at least 7 days before any surgical procedure and efforts were made to minimize animal suffering and the number of animals used.

### Induction of Transient Focal Cerebral Ischemia and Drug Treatment

Male PTGS2 knockout (referred in this manuscript as COX-2−/−) and wild-type mice on a C57BL/6 background were obtained from Taconic. Focal cerebral ischemia was induced with a retro-mesencephalic artery ligation as previously described (25). A middle cerebral artery occlusion was performed using a 4-0 silk suture. The suture was pulled to occlude the MCA for 90 min. Animals were then reperfused for 15 min. MCAO was confirmed by the absence of a positive TTC staining in the ischemic hemisphere (25).

### Abbreviations:

- COX-2, cyclooxygenase-2; NSAIDs, non-steroidal anti-inflammatory drugs; AA, arachidonic acid; PGE2, prostaglandin E2; COX-2−/−, COX-2 knockout; BBB, blood-brain barrier; MMP-9, matrix metalloproteinase-9; TJPs, tight junction proteins; MCAO, middle cerebral artery occlusion; CCA, common carotid artery; ECA, external carotid artery; ICA, internal carotid artery; DMSO, dimethyl sulfoxide; TTC, 2,3,5-triphenyltetrazolium chloride; PBS, phosphate-buffered saline; BIPA, radioimmunoprecipitation; IgG, immunoglobulin G; Hb, hemoglobin; ZO-1, zonula occludens-1; JA-M-A, junctional adhesion molecule-A; MPO, myeloperoxidase; NE, neutrophil elastase; ICN2, lipocalin-2; RFUs, relative fluorescence units; TJs, tight junctions; AJs, adherens junctions; MMPs, matrix metalloproteinases; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor alpha.
by occlusion of right middle cerebral artery (MCA) using a silicone-coated filament as described previously by our group (29, 30). Briefly, mice (10–12 weeks old) were anesthetized with 3% isoflurane and surgical levels of anesthesia were maintained by inhalation of 1.5–2% isoflurane in medical grade oxygen. The right common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were exposed via a midline vertical incision in the anterior neck. The CCA was ligated with a 6-0 silk suture at the proximal portion from the carotid bifurcation. A 12 mm length of a 6-0 silicone-coated nylon filament (Doccol, Cat. No. 602123) was inserted into the CCA and advanced gently into the ICA ~9–10 mm from the carotid bifurcation until a mild resistance was felt and cerebral blood flow (CBF) was reduced by at least 75% of the baseline value, as assessed by laser Doppler flowmetry. After 60 min of MCA occlusion, the filament was gently retracted to allow reperfusion. The skin was closed and anesthesia was discontinued, and the mice were allowed to recover in a temperature-controlled chamber. Sham-operated animals received the same surgical procedures except for the MCA occlusion. For the treatment with vehicle or CAY10404 (Cat. No. 70210, Cayman Chemical, Ann Arbor, MI), a highly selective COX-2 inhibitor, wild-type mice were injected with a single dose of vehicle (0.1% DMSO in 10% Solutol dissolved in physiological saline) or CAY10404 (10 mg/kg; i.p.) at the start of reperfusion. The selectivity of CAY10404 toward COX-2 is comparable to the selectivity index of second-generation selective COX-2 inhibitors, such as valdecoxib and etoricoxib (31). This dose of CAY10404 was selected based on previous reports showing antinociceptive and anti-inflammatory effects in mice (32, 33).

Measurement of Infarct Volume
Brain infarct volume was measured using 2,3,5-triphenyltetrazolium chloride (TTC) staining as described in detail in our previous studies (29, 34). Mice were euthanized at 24 h post-MCAO and brains were collected after transcardiac perfusion with ice-cold saline. The brain was placed in a slicing matrix (Zivic Instruments, Pittsburgh, PA, USA) and sliced into six 1-mm thick coronal sections. Sections were stained with 2% TTC in phosphate-buffered saline (PBS) for 30 min at room temperature followed by fixation with 4% paraformaldehyde (PFA) in PBS, then scanned at 600 dpi by a HP Scanjet 8300 scanner (Palo Alto, CA). Infarct volume corrected for edema was determined with Adobe Photoshop as we have previously reported (29, 34–37).

Protein Extraction From Brain Tissue
At 24 h after MCAO, mouse brains were dissected out after transcardiac perfusion with ice-cold saline, and ipsilateral and contralateral cerebral cortices were collected on dry ice and immediately stored at −80°C until further processing. Cortical tissue was homogenized in radioimmunoprecipitation (RIPA) lysis buffer containing protease and phosphatase inhibitors as detailed in our previous report (29). Protein concentration in resulting tissue homogenates was determined by Pierce™ BCA assay kit (Cat. No. 23227, Thermo Scientific, Rockford, IL) and samples were aliquoted and stored at −80°C until use.

Immunoblotting Analysis
Fifty micrograms of protein were separated on 4–20% SDS-polyacrylamide gels and then transferred onto nitrocellulose membranes. Membranes were then blocked for 1 h at room temperature with 5% non-fat milk in Tris-buffered saline. Thereafter, the membranes were incubated at 4°C overnight with primary mouse anti-IgG antibody (1:2,000; Cat. No. 7076; Cell Signaling Technology), rabbit anti-ZO-1 antibody (1:500; Cat. No. 61-7300; Invitrogen), rabbit anti-occludin antibody (1:500; Cat. No. 61-7300; Invitrogen), rabbit anti-JAM-A antibody (1:5,000; Cat. No. ab52647; Abcam), goat anti-Collagen IV antibody (1:500; Cat. No. 1340-01; Southern Biotech), rabbit anti-MMP-9 antibody (1:1,000; Cat. No. sc-6841R; Santa Cruz Biotechnology), rabbit anti-MPO antibody (1:1,000; Cat. No. sc-16128-R; Santa Cruz Biotechnology), or mouse anti-β-actin antibody (1:10,000; Cat. No. A1978; Sigma). The membranes were then washed with TBST three times at 5 min intervals, incubated with goat anti-rabbit IRDye 800CW (1:30,000; Li-Cor, Lincoln, NE), donkey anti-mouse IRDye 680LT (1:40,000; Li-Cor), or donkey anti-goat IRDye 800CW (1:30,000; Li-Cor) secondary antibodies for 1 h at room temperature. Immunoreactive bands were visualized and densitometrically analyzed using Odyssey infrared scanner and Image Studio 2.0 software (Li-Cor).

ELISA
Levels of IgG and hemoglobin (Hb) in the brain parenchyma were measured using commercial ELISA kits (Cat. Nos. E-90G and E-90HM, respectively; Immunology Consultants Laboratory, Inc.; Portland, OR) according to the manufacturer's instructions since extravasation of these plasma proteins into the brain tissue is a sensitive marker of BBB disruption after ischemia. A total of 50 µg protein extracted from ipsilateral and contralateral cerebral cortex of mouse brain were used for the IgG measurement while 15 µg of total protein were used for the Hb measurement. All samples were assayed in duplicated and optical absorbance at 450 nm was measured with a Synergy™ HT Multi-Mode Plate Reader (Biotek Instruments, Winooski, VT).

Levels of neutrophil elastase (NE) and lipocalin-2 (LCN2, also known as neutrophil gelatinase-associated lipocalin) in ipsilateral and contralateral cerebral cortices were measured using specific ELISA kits purchased from TSZ Scientific (NE: Cat. No. M7718; Framingham, MA) and R&D Systems (LCN2: Cat. No. MLCN20; Minneapolis, MN), respectively. According to the manufacturer's instructions, a total of 50 µg of protein from ipsilateral and contralateral cortices of mouse brains were used for the NE measurement while 40 µg of protein were used for the LCN2 measurement.

Measurement of MMP-9 Enzymatic Activity
MMP-9 enzymatic activity in cortical homogenate was measured using an immunocapture assay method as reported in detail in our previous studies (29, 38). Briefly, 96-well high binding plates (Cat. No. 655077; Greiner Bio-One, Monroe, NC) were
coated with MMP-9 antibody (Cat. No. sc-6841R; Santa Cruz Biotechnology, Dallas, TX) following protein A/G pre-coating. Then, a total of 50 µg protein extracted from mouse brain cerebral cortex was added to each well and incubated at 4°C overnight. After incubation, wells were washed with TCNB buffer (50 mM Tris, 10 mM CaCl$_2$, 150 mM NaCl, 0.05% Brij-35) and 1 µM of 520 MMP FRET substrate III (Cat. No. 60570-01; AnaSpec, San Jose, CA) was added. Plates were incubated for 48 h at 37°C, then relative fluorescence units (RFUs) were read at excitation/emission wavelengths of 485/528 nm in a Synergy400 HT Multi-Mode Plate Fluorescence Reader. The average value from one paired substrate control wells was used to subtract baseline fluorescence from sample wells.

**Power Analysis, Randomization, Blinding, and Statistics**

We performed an *a priori* sample size calculation using the G*P*ower v.3.1 software. Using means and standard deviations from our preliminary studies in this mouse ischemic stroke model, we calculated Cohen effect size (d). We compared two independent groups in a two-tailed unpaired t-test using $\alpha = 0.05$, and $\beta$ (type II error) of 0.2 with a power of 80%. The present study was powered with the expectation that we will detect a difference in plasma protein extravasation between genotypes of at least 25%. For the difference to become statistically significant, we calculated a sample size of $n = 9$ with an effect size of $d = 1.4138$. All mice were randomly allocated to experimental groups using the randomization tool developed by GraphPad Prism (http://www.graphpad.com/quickcalcs/randomize1.cfm). The investigators performing stroke surgeries, euthanizing animals, or performing outcome assessments (molecular biology analyses, infarct size calculation) had no knowledge of the genotype or treatment group to which an animal belonged. All values were expressed as mean ± standard deviation (SD). An independent unpaired Student's t-test was performed for comparison between two groups and a two-way ANOVA followed by Bonferroni post-tests for comparisons of multiple groups. GraphPad Prism 6 was used to conduct data analysis, and $P < 0.05$ was considered statistically significant.

**RESULTS**

**COX-2 Deficiency Significantly Reduces Stroke-Induced BBB Breakdown and Hemorrhagic Transformation**

Inflammatory responses significantly contribute to BBB breakdown, which is the main cause of hemorrhagic transformation after ischemic stroke (39). Since COX-2 actively participates in neuroinflammation after stroke (6, 7, 12), we sought to determine whether COX-2 deficiency lessens BBB breakdown and hemorrhagic transformation utilizing COX-2 null mice and their wild-type controls subjected to 60 min of MCAO followed by 24 h of reperfusion. To quantify BBB disruption, we measured levels of IgG extravasated into the brain using immunoblotting. In COX-2$^{-/-}$ mice, IgG was dramatically increased in the ipsilateral cerebral cortex. BBB injury was largely reduced in COX-2$^{-/-}$ mice compared to their wild-type controls, as demonstrated by significantly lower levels of both IgG chains in the ischemic brain (Figures 1A,B).

To examine whether COX-2 deficiency influences stroke-induced hemorrhagic conversion, we quantified hemoglobin (Hb) levels in brain homogenates utilizing a highly sensitive ELISA in both COX-2$^{+/+}$ and COX-2$^{-/-}$ mice at 24 h after ischemia. There was a significant reduction in Hb content in the ipsilateral cortex of COX-2$^{-/-}$ mice compared with wild-type animals (Figure 1C). Collectively, these data suggest that COX-2 is an important mediator of BBB damage and hemorrhagic transformation following transient ischemic stroke.

**COX-2 Deficiency Ameliorates Stroke-Induced Damage to Structural Components of the Neurovascular Unit**

The tight junction proteins (TJPs), ZO-1 and occludin, as well as the basal lamina protein, collagen IV, are critical for maintaining the integrity of the neurovascular unit (40, 41). Junctional adhesion molecule-A (JAM-A) is another BBB structural component that has been shown to facilitate tight junction assembly and modulate BBB permeability (42–44). Immunoblotting analysis of ZO-1, occludin, JAM-A, and collagen IV was performed in cortical homogenates of COX-2$^{+/+}$ and COX-2$^{-/-}$ mice subjected to 60 min of MCAO or sham surgery and 24 h of reperfusion. In the ipsilateral cerebral cortex of COX-2$^{+/+}$ mice, levels of ZO-1, occludin, JAM-A, and collagen IV were markedly decreased after stroke. In COX-2$^{-/-}$ mice, the damage to these BBB structural proteins was profoundly attenuated (Figure 2). This suggests that COX-2 deficiency protects against stroke-induced loss of proteins that compose the tight junctions and basal lamina. These findings help to explain the significant neurovascular protection seen in COX-2$^{-/-}$ after ischemia.

**Genetic Deletion of COX-2 Reduces MMP-9 Protein Levels and Enzymatic Activity**

MMP-9 is a potent proteinase involved in the degradation of extracellular matrix and TJPs, thus resulting in the BBB disruption (21, 23). MMP-9 protein levels and its activity in cerebral cortex were measured using immunoblotting and fluorometric immunocapture assay methods. As shown in Figures 3A,B, MMP-9 levels in the ipsilateral cortex of COX-2$^{+/+}$ and COX-2$^{-/-}$ mice were both dramatically increased after stroke, but much lower levels of MMP-9 were observed in COX-2$^{-/-}$ mice compared to the wild-type animals. Similarly, stroke resulted in a dramatic increase in MMP-9 activity in the ipsilateral cortex of COX-2$^{+/+}$ mice, and this increase was significantly attenuated in COX-2$^{-/-}$ mice (Figure 3C). These findings suggest that COX-2 is involved in MMP-9-mediated BBB damage in ischemic stroke.
FIGURE 1 | COX-2 genetic inactivation protects against stroke-induced BBB breakdown and hemorrhagic transformation. BBB permeability was assessed by immunoglobulin G (IgG) extravasation into the brain, as quantified by immunoblotting. (A) Representative western blot for IgG (heavy and light chains) in the cerebral cortex of wild-type (COX-2+/+) and knockout (COX-2−/−) mice; i, ipsilateral; c, contralateral. There is a significant reduction in BBB damage in COX-2−/− mice compared to wild-type controls at 24 h following 60 min of temporary middle cerebral artery occlusion (MCAO). (B) Densitometric analysis of heavy and light chains of IgG normalized to β-actin in the ischemic cortex of mice of both genotypes. Unpaired t-test, *P < 0.05 and **P < 0.01. (C) Hemoglobin (Hb) levels in the brains were quantified using a highly sensitive ELISA as a measure of hemorrhagic transformation following ischemia. COX-2−/− mice had a significant reduction in Hb levels after stroke compared to COX-2+/+ controls. Two-way ANOVA with Bonferroni post-tests. *P < 0.05, **P < 0.01, and ***P < 0.001. Bars represent mean ± SD. n = 10 in MCAO groups of each genotype. Sham-operated groups (n = 3).

COX-2 Deficient Mice Show Less Neutrophil Infiltration and Reduced Protein Levels of Neutrophil Elastase (NE) and Lipocalin-2 (LCN2) After Experimental Stroke

To examine whether COX-2 deficiency affects neutrophil infiltration in ischemic stroke, levels of myeloperoxidase (MPO, an indicator of neutrophil infiltration into the brain parenchyma), neutrophil elastase (NE), and lipocalin-2 (LCN2, also known as neutrophil gelatinase-associated lipocalin) were measured in cortical homogenates of COX-2+/+ and COX-2−/− mice at 24 h after MCAO. Immunoblotting and densitometric analysis show that MPO protein levels were dramatically induced by stroke in the ipsilateral cortex of COX-2+/+ mice, and very low levels of MPO were detected in the COX-2−/− mice compared to the wild-type animals (Figures 4A,B). In line with these observations, levels of NE and LCN2 as measured by specific ELISA kits, in the ipsilateral cortex of COX-2−/− mice were dramatically reduced after stroke compared to the wild-type animals (Figures 4C,D). Together, these data suggest that COX-2 contributes to neutrophil infiltration into the injured brain during ischemic stroke.

Selective Pharmacological Inhibition of COX-2 Reduces Ischemia-Induced Neurovascular Injury and MMP-9 Activity

Data from our experiments utilizing COX-2−/− mice suggest that increased COX-2 activity is a key pathological event in stroke-induced neurovascular injury. However, there might be compensatory changes in germline COX-2−/− mice, which could explain decreased BBB damage after stroke. To address this potential limitation of our genetic knockout experiments, we utilized a different experimental approach using the pharmacological COX-2 inhibitor, CAY10404. Similar to COX-2 genetic deletion, post-ischemic treatment with the highly selective COX-2 inhibitor, CAY10404, significantly reduced stroke size (Figure 5A), IgG extravasation (Figure 5B) and hemorrhagic transformation (Figure 5C) compared to the vehicle-treated group. Since the treatment with the COX-2 inhibitor might lessen the extent of BBB damage by reducing infarct size, we corrected for this potential confounder by expressing the extent of BBB disruption relative to the infarct volume (Figures 5D,E). Thus, the BBB permeability is normalized to the infarct to correct for smaller lesion sizes in animals receiving CAY10404. After correcting for infarct volume, treatment with CAY10404 significantly reduced IgG and Hb levels in ischemic brain (Figures 5D,E), which further supports the vasculoprotective effects of COX-2 inhibition. In line with the BBB permeability data, stroke-induced loss of tight junction proteins including ZO-1 and occludin was significantly attenuated by CAY10404 treatment in the ischemic brain (Figures 5G–I), which were associated with significant reduction of MMP-9 activity.
Reduced damage to BBB structural components in COX-2 deficient mice after stroke. Ischemia-induced loss of proteins composing the tight junctions, adherens junctions, and basal lamina significantly increases BBB permeability. COX-2 null mice displayed a reduced loss of ZO-1, occludin, JAM-A, and collagen IV after ischemic stroke compared to wild-type controls.

(A) Representative immunoblot images for several BBB structural proteins. i, ipsilateral; c, contralateral.

Densitometric analyses normalized to β-actin are presented for ZO-1 (B), occludin (C), JAM-A (D), and collagen IV (E). Two-way ANOVA with Bonferroni post-tests.

*P < 0.05, **P < 0.01, and ***P < 0.001. Data are presented as mean ± SD. n = 10 in MCAO groups of each genotype. Sham-operated groups (n = 3).
Genetic deletion of COX-2 significantly reduces MMP-9 activity and protein content in the ischemic brain. Transient focal cerebral ischemia followed by 24 h of reperfusion produced a dramatic increase in MMP-9 protein levels in the ipsilateral cerebral cortex as shown by immunoblotting. COX-2−/− mice had a significant reduction in MMP-9 levels after ischemia compared with COX-2+/+. (A) Representative western blot for MMP-9 in cortical homogenates from ipsilateral (i) and contralateral (c) cortex. (B) Densitometric analysis of MMP-9 relative to β-actin. Reduced MMP-9 protein content was seen in COX-2−/− compared with COX-2+/+ at 24 h following MCAO. (C) Fluorometric immunocapture assay of MMP-9 activity measured at 24 h in the cerebral cortex following transient ischemia showed a significant increase in COX-2+/+ mice (~8-fold increase with respect to contralateral). Compared with the wild-type, COX-2−/− mice had a significant reduction in MMP-9 activity. For (B,C), statistical analyses were performed using two-way ANOVA with Bonferroni post-tests. Significance was defined as *P < 0.05, **P < 0.01, and ***P < 0.001. Data are presented as mean ± SD. n = 10 in ischemic groups of each genotype. Sham-operated groups (n = 3).

Taken together, these findings suggest that genetic deficiency or pharmacological inhibition of COX-2 significantly reduces stroke-induced neurovascular injury (Figure 5F).
possibly by reducing MMP-9-mediated proteolysis of BBB structural components.

**DISCUSSION**

In the present study, we examined the effects of COX-2 blockade in a mouse model of transient focal cerebral ischemia. We found that COX-2 deficient mice had a significant reduction of BBB damage, hemorrhagic transformation, and neutrophil infiltration as compared with wild-type mice after 60 min of MCAO and 24 h of reperfusion, where this neurovascular protection is associated with reduced MMP-9 expression/activity. To further rule out the potentially compensatory effects of COX-2 gene deficiency in mice following stroke, we also investigated the effects of CAY10404, a highly selective COX-2 inhibitor, on BBB damage, hemorrhagic transformation, and MMP-9 activity in wild-type mice subjected to focal ischemia. As a result, pharmacological inhibition of COX-2 with CAY10404 treatment resulted in reduced infarct volume, BBB damage, hemorrhagic transformation and MMP-9 activity. To our knowledge, this study provides the first experimental evidence implicating COX-2 as a key mediator in the cascade of events leading to increased MMP-9 expression and activation in the ischemic brain resulting in BBB damage.

COX-2 inhibition has emerged as a potential therapeutic strategy for cerebral ischemia, targeting critical pathophysiological events that exacerbate the initial brain damage triggered by the ischemic episode. Previous findings from our group and others have demonstrated that COX-2 selective inhibitors, such as nimesulide (9, 11, 12), rofecoxib (13), SC58236 (14, 17), and NS398 (18) exert beneficial effects in ischemic stroke. Here, we investigated the effects of genetic deficiency of COX-2 or inhibition of COX-2 with its highly selective inhibitor, CAY10404, on BBB damage and hemorrhagic transformation in a transient focal cerebral ischemia model in mice. Since IgG or Hb are barely detected in the non-injured brain due to the barrier function of an intact neurovascular unit, stroke-induced BBB damage will facilitate the leakage of these plasma proteins into the ischemic area. Our results showed that levels of IgG and Hb were significantly increased in the ischemic cerebral cortex of wild-type mice compared to sham-operated group, while the increases in these two plasma proteins were dramatically reduced in the COX-2−/− mice or with post-ischemic treatment of CAY10404, suggesting that genetic deletion or pharmacological inhibition of COX-2 could attenuate stroke-induced BBB damage and hemorrhagic transformation. These findings are in line with previous reports that COX-2 deficient mice show smaller infarct volume than wild-type animals after transient MCAO (15, 18), whereas overexpression of COX-2 exacerbate the stroke outcomes (17).

Cellular components of the neurovascular unit, such as brain microvascular endothelial cells, pericytes, astrocytic end feet, neuronal processes, and perivascular microglia act in concert to provide a physiological barrier that guarantees brain homeostasis (41, 45, 46). Structural components of the basal lamina, tight junctions (TJs) and adherens junctions (AJs) play key roles in the maintenance of the integrity of the BBB (41). To explore the underlying structural components responsible for the COX-2-mediated BBB disruption in ischemic stroke, ZO-1 and occludin (two critical TJs) as well as the basal lamina protein, collagen IV, were measured in ischemic brain of COX-2+/+ and COX-2−/− mice since they are important in the maintenance of BBB integrity (40, 41). We found that levels of ZO-1, occludin and collagen IV were dramatically decreased in the ischemic cerebral cortex of wild-type mice as compared with sham-operated animals, which is consistent with previous reports showing that loss of specific TJs or basal membrane proteins is associated with BBB opening (46–48). Importantly, genetic deletion of COX-2 prevented the stroke-induced loss of these critical structural proteins of the BBB and post-ischemic treatment with CAY10404 also significantly reduced the TJs breakdown. In agreement with a previous report showing a decrease of JAM-A expression associated with BBB breakdown in a rat cortical cold injury model (44), we found a dramatic decrease of JAM-A protein levels, another BBB structural component, in ischemic cortex at 24 h of reperfusion in wild-type mice subjected to transient MCAO. Stroke-induced the loss of JAM-A was significantly restored in COX-2 deficient mice. Taken together, these findings strongly suggest that genetic deficiency or pharmacological inhibition of COX-2 mediates neurovascular protection in ischemic stroke through the preservation of specific BBB structural proteins.

MMP-9 is an important gelatinase that belongs to the MMP family involved in the degradation of extracellular matrix and tight junction proteins, thus leading to the BBB disruption (21, 23). Our data indicate that genetic deletion or pharmacological inhibition of COX-2 reduces MMP-9 production in stroke, which reveals for the first time that COX-2 activity may contribute to MMP-9 expression and activation in the ischemic brain, and the resulting BBB damage. However, it is not clear which downstream effectors of COX-2 mediate MMP-9 expression/activation in ischemic stroke. Previous studies from our group and others have demonstrated that COX-2 levels are increased in the ischemic brain, which is associated with the generation of large amounts of PGE2 (6, 10, 12), one of the major proinflammatory prostanoids formed by the COX-2 pathway. In support, neuronal overexpression of COX-2 in mice results in a dramatic increase (~10-fold) in the brain PGE2 levels compared with wild-type mice, which results in a marked increase in stroke volume (17). Conversely, genetic deletion or pharmacological inhibition of COX-2 results in
Pharmacological inhibition of COX-2 protects against stroke-induced BBB damage, hemorrhagic transformation, increased MMP-9 activity, and loss of tight junction proteins. CAY10404, a highly selective COX-2 inhibitor, was administered intraperitoneally at the start of reperfusion to wild-type mice subjected to MCAO. Ischemic controls received the vehicle. (A) Treatment with CAY10404 significantly reduced infarct size at 24 h after stroke. Unpaired t-test, *P < 0.05. (B) Extravasation of IgG into the ischemic cerebral cortex was significantly reduced by post-ischemic CAY10404 administration. Two-way ANOVA with Bonferroni post-hoc test. **P < 0.01 and ***P < 0.001. (C) Reduced hemorrhagic transformation in CAY10404-treated mice at 24 h after stroke, as quantified by brain (Continued)
smaller infarct volume, together with decreased levels of PGE2 in the ischemic brain after stroke (15, 18). Currently, there is no direct evidence showing that COX-2-derived PGE2 contributes to the MMP-9 activation and the resulting BBB damage in ischemic brain. However, the COX-2/PGE2 pathway has been widely reported to be involved in the upregulation of MMP-9 in cancer cells and primary monocytes/macrophages (25–28, 49–52). In the pancreatic cancer cell line, BxPC-3, inflammatory stimuli, such as lipopolysaccharides (LPS) or tumor necrosis factor alpha (TNF-α) significantly increase the expression of COX-2, PGE2, and MMP-9, and siRNA knockdown of COX-2 or treatment with the COX-2 selective inhibitor NS398 significantly reduces the increase in MMP-9 expression (28).

In the human leukemic T cell line, HSB.2, PGE2 directly induces MMP-9 transcription, an effect that is mediated by the EP3 subtype of PGE2 receptor (49). The addition of PGE2 to macrophage cultures stimulates the expression of both urokinase-type plasminogen activator and MMP-9, and siRNA knockdown of COX-2 or treatment with the COX-2 selective inhibitor NS398 significantly reduces the increase in MMP-9 expression (28).

The source of MMP-9 produced in ischemic brain is still controversial. Infiltrating neutrophils are believed to be the major source of active MMP-9 in cerebral ischemia (53–56). Neutrophils are present early in the ischemic tissue contributing to reperfusion injury (55–57). Our data indicate that myeloperoxidase (MPO, an indicator of peripheral neutrophil infiltration), neutrophil elastase (NE), and lipocalin-2 (LCN2, also known as neutrophil gelatinase-associated lipocalin) are markedly increased in the ischemic brain, and that the increased levels of these markers of neutrophil infiltration are significantly reduced in COX-2−/− mice. This suggests that reduced neutrophil infiltration may be involved in limiting MMP-9 production, thus resulting in less BBB damage in COX-2−/− mice following stroke. As an alternative interpretation, it is also possible that decreased MMP-9 levels/activity following COX-2 blockade is due to reduced activation of microglial cells and astrocytes, which would result in BBB protection after stroke (21, 23, 58–60). Less BBB damage in COX-2−/− mice or in animals treated with the COX-2 inhibitor would limit the infiltration of MMP-9-laden neutrophils into the damaged brain (45, 61). Future studies are needed to explore the causal link between BBB damage, increased MMP-9 levels and neutrophil infiltration in the context of ischemic stroke, as well as determining how blockade of COX-2-dependent pathways modulates the activation of glial cells and neutrophils to protect the BBB after ischemic injury.

Neutrophil elastase and lipocalin-2 are two critical inflammatory mediators linked to neurovascular injury in stroke. NE belongs to the chymotrypsin-like family of serine proteases and plays an important role in immunity and host defense. This protease is mainly produced by neutrophils. Under pathological conditions, excess production of NE could result in tissue damage by degrading the extracellular matrix (62, 63). We found a significant increase in the levels of NE in the ipsilateral cerebral cortex at 24 h following transient focal cerebral ischemia, which is in line with the results from a previous study (64). Genetic deletion or pharmacological inhibition of NE significantly reduces infarct size, BBB disruption, vasogenic edema, as well as diminishes leukocyte adherence to the brain endothelium (64). LCN2 is another inflammatory mediator that is released from astrocytes, endothelial cells, and infiltrating neutrophils following ischemic brain injury (65–68). Consistent with these studies, we found that the levels of LCN2 increase dramatically in the stroked brain. Since both NE and LCN2 have been shown to mediate neuroinflammation and BBB damage in stroke (64–68), reduced levels of NE and LCN2 in COX-2-deficient animals could be a potential mechanism underlying the vasculoprotective effects of COX-2 blockade in stroke.

In summary, our data demonstrate the beneficial effects of genetic deletion or pharmacological inhibition of COX-2 on preservation of BBB integrity, maintenance of structural components of the neurovascular unit, reduction of MMP-9 expression/activity as well as limitation of neutrophil infiltration in a mouse model of transient focal cerebral ischemia. These results indicate that MMP-9 is one of the downstream effectors in COX-2/PGE2-mediated BBB damage in ischemic stroke. Targeting the COX-2/MMP-9 pathway could represent a promising strategy to reduce brain injury and preserve the integrity of the BBB following stroke.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
ETHICS STATEMENT
The animal study was reviewed and approved by University of Florida Institutional Animal Care and Use Committee (protocol # 201607934).

AUTHOR CONTRIBUTIONS
CY, YY, KD, and EC-J performed the experimental procedures. CY, GR, and EC-J designed the research and planned all the experiments. CY, KD, and EC-J analyzed the data and prepared the figures. CY and EC-J wrote the article. EC-J conceived and led the project. All the authors read and approved the final version of the manuscript.

FUNDING
This research was supported by the NIH grant NS065849. Additional support for this project was provided by the Brain and Spinal Cord Injury Research Trust Fund, McKnight Brain Institute, University of Florida and NIH grants NS103094 and NS109816.

REFERENCES
1. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. (2000) 5:75–86. doi: 10.1038/nrd1929
2. Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxygenase-2 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther. (2003) 315:1–7. doi: 10.1124/jpet.105.085431
3. Candelario-Jalil E, Fiebich BL. Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des. (2008) 14:1401–18. doi: 10.2174/13816120878480216
4. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. (2000) 69:145–82. doi: 10.1146/annurev.biochem.69.1.145
5. Collaco-Moraes Y, Aspey B, Harrison M, de Bellerache J. Cyclooxygenase-2 messenger RNA induction in focal cerebral ischemia. J Cereb Blood Flow Metab. (1996) 16:1356–72. doi: 10.1097/00004467-199611000-00035
6. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclooxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. (1997) 17:2746–55. doi: 10.1523/JNEUROSCI.17-08-0274.1997
7. Planas AM, Soriano MA, Rodriguez-Farre E, Ferrer I. Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci Lett. (1995) 200:187–90. doi: 10.1016/0304-3900(95)12108-G
8. Yu L, Yang B, Wang J, Zhao L, Luo W, Jiang Q, et al. Time course change of COX2-PGII/TX2A following global cerebral ischemia reperfusion injury in rat hippocampus. Behav Brain Funct. (2014) 10:42. doi: 10.1186/1744-9081-10-42
9. Candelario-Jalil E, Alvarez D, Merino N, Leon OS. Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils. Neurosci Res. (2003) 47:245–53. doi: 10.1016/S0016-0102(03)00184-6
10. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Alvarez D, Al-Dalain S, Martinez G, et al. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem. (2003) 86:545–55. doi: 10.1046/j.1471-4159.2003.01812.x
11. Candelario-Jalil E, Mhadi NH, Gonzalez-Falcon A, Garcia-Cabrera M, Munoz E, Leon OS, et al. Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat. J Neuroinflammation. (2005) 2:3. doi: 10.1186/1742-2094-2-3
12. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL. Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J Neurochem. (2007) 100:1108–20. doi: 10.1111/j.1471-4159.2006.04280.x
13. Xiang Z, Thomas S, Pasinetti G. Increased neuronal injury in transgenic mice with neuronal overexpression of human cyclooxygenase-2 is reversed by hypothermia and rofecoxib treatment. Curr Neurovasc Res. (2007) 4:274–9. doi: 10.2174/1567207782446342
14. Govoni S, Maseoero E, Favalli L, Rozza A, Scelsi R, Viappiani S, et al. The cyclooxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neurosci Lett. (2001) 303:91–4. doi: 10.1016/S0304-3904(01)01675-5
15. Iadecola C, Niwa K, Bogawa S, Zhao X, Nagayama M, Araki E, et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA. (2001) 98:1294–9. doi: 10.1073/pnas.98.3.1294
16. Sasaki T, Kitagawa K, Yamagata K, Takemiy A, Tanaka S, Omura-Matsuoka E, et al. Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J Cereb Blood Flow Metab. (2004) 24:107–13. doi: 10.1097/01.WCB.0000100065.36077.4A
17. Dore S, Otsuka T, Mito T, Sugo N, Hand T, Wu L, et al. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol. (2003) 53:155–62. doi: 10.1002/ana.10612
18. Kunz A, Anrather J, Zhou P, Orilo M, Iadecola C. Cyclooxygenase-2 does not contribute to post ischemic production of reactive oxygen species. J Cereb Blood Flow Metab. (2007) 27:545–51. doi: 10.1038/sj.jcbfm.9600369
19. Schmidley JW, Dadson J, Iyer RS, Salomon RG. Brain tissue injury and blood-brain barrier opening induced by injection of LGE2 or PGE2. Prostaglandins Leukot Essent Fatty Acids. (1992) 47:105–10. doi: 10.1095/1992-3278(92)90145-9
20. Romanic AM, White RE, Arleth AJ, Olsheln EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. (1998) 29:1020–30. doi: 10.1161/01.STR.29.5.1020
21. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke. (1998) 29:2189–95. doi: 10.1161/01.STR.29.10.2189
22. Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol. (1998) 274:R1203–11. doi: 10.1152/ajpregu.1998.274.5.R1203
23. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. (2007) 27:697–709. doi: 10.1038/jj.cbfm.9600375
24. Candelario-Jalil E, Yang R, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. (2009) 158:983–94. doi: 10.1016/j.neuroscience.2008.06.025
25. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. (2000) 60:4629–37.
26. Ishizaki T, Katsumata K, Tsuchida A, Wada T, Mori Y, Hisada M, et al. Endolol, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med. (2006) 17:357–62. doi: 10.3892/ijmm.17.2.357
Yang C, Hawkins KE, Dore S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. *Am J Physiol Cell Physiol.* (2019) 316:C135–53. doi: 10.1152/ajpcell.00136.2018

Yang X, Andjeljkovic AV, Zhu L, Yang T, Bennett MVL, Chen J, et al. Blood-brain barrier dysfunction and recovery after ischemic stroke. *Prog Neurobiol.* (2018) 163:164–144. doi: 10.1016/j.pneurobi.2017.10.001

Jiao H, Wang Z, Liu Y, Wang P, Xue Y. Specific role of tight junction proteins Claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. *J Mol Neurosci.* (2011) 44:1330–9. doi: 10.1007/s12031-011-9496-4

Hou H, Zhang G, Wang H, Gong H, Wang C, Zhang X. High matrix metalloproteinase-9 expression induces angiogenesis and basement membrane degradation in stroke-proteins spontaneously hypertensive rats after cerebral infarction. *Neural Regen Res.* (2014) 9:1154–62. doi: 10.4103/1673-5374.135318

Zeng L, An S, Goetzl EJ. Regulation of expression of matrix metalloproteinase-9 in early human T cells of the HS2.2 cultured line by the EP3 subtype of prostaglandin E2 receptor. *J Biol Chem.* (1996) 271:27744–50. doi: 10.1074/jbc.271.44.2774

Khan KM, Howe LR, Falcone DJ. Extracellular matrix-induced cyclooxygenase-2 regulates macrophage protein expression. *J Biol Chem.* (2004) 279:22039–46. doi: 10.1074/jbc.M312735200

Pavlovic S, Du B, Sakamoto K, Khan KM, Natarajan C, Breyer RM, et al. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. *J Biol Chem.* (2006) 281:3321–8. doi: 10.1074/jbc.M508846200

Cipollone F, Favia ML, Iezzi A, Caccarullo C, De CD, Ucchino S, et al. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. *Arterioscler Thromb Vasc Biol.* (2005). 25:1925–31. doi: 10.1161/01.ATV.0000177814.41505.41

Justicia C, Panes I, Sole S, Cervera A, Deufoe R, Chamorro A, et al. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. *J Cer eb Blood Flow Metab.* (2003) 23:430–40. doi: 10.1016/S0161-6412(03)00515.C8

Giddam JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. *Am J Physiol Heart Circ Physiol.* (2005) 289:H558–68. doi: 10.1152/ahpc.01275.2004

Turner RJ, Sharp FR. Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke. *Front Cell Neurosci.* (2016) 10:56. doi: 10.3389/fncel.2016.00056

Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic stroke: translational insights from experimental studies. *J Cereb Blood Flow Metab.* (2015) 35:888–901. doi: 10.1038/jcbfm.2015.45

Kochanek PM, Hallenbeck JM. Poly(ADP-ribose) polymerase γ mediates leukocyte recruitment. *J Cereb Blood Flow Metab.* (2004) 23:1089–99. doi: 10.1097/00004437-200408010-00008

Al Zoppo GJ, Frankowski H, Gu YH, Osada T, Kanazawa M, Milner R, et al. Neutrophil infiltration increases matrix metalloproteinase-9 activity in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. *J Cereb Blood Flow Metab.* (2007) 27:1371–8. doi: 10.1038/jcbfm.2007.77

Basso G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. *Physiol Rev.* (2004) 84:869–901. doi: 10.1152/physrev.00035.2003

Vazquez EA, Vazquez-Lopez ME. Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat. *Gastroenterology.* (2002) 123:1385–90. doi: 10.1053/gast.2002.30348

Weissmann G, Smolen IE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. *N Engl J Med.* (1980) 303:27–34. doi: 10.1056/NEJM198007033030109
63. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. *Nat Rev Immunol.* (2011) 11:519–31. doi: 10.1038/nri3024
64. Stowe AM, Adair-Kirk TL, Gonzales ER, Perez RS, Shah AR, Park TS, et al. Neutrophil elastase and neurovascular injury following focal stroke and reperfusion. *Neurobiol Dis.* (2009) 35:82–90. doi: 10.1016/j.nbd.2009.04.006
65. Zhao N, Xu X, Jiang Y, Gao J, Wang F, Xu X, et al. Lipocalin-2 may produce damaging effect after cerebral ischemia by inducing astrocytes classical activation. *J Neuroinflammation.* (2019) 16:168. doi: 10.1186/s12974-019-1556-7
66. Suk K. Lipocalin-2 as a therapeutic target for brain injury: an astrocentric perspective. *Prog Neurobiol.* (2016) 144:158–72. doi: 10.1016/j.pneurobio.2016.08.001
67. Wang G, Weng YC, Han X, Whaley JD, McCrae KR, Chou WH. Lipocalin-2 released in response to cerebral ischaemia mediates reperfusion injury in mice. *J Cell Mol Med.* (2015) 19:1637–45. doi: 10.1111/jcmm.12538
68. Jin M, Kim JH, Jang E, Lee YM, Soo Han H, Woo DK, et al. Lipocalin-2 deficiency attenuates neuroinflammation and brain injury after transient middle cerebral artery occlusion in mice. *J Cereb Blood Flow Metab.* (2014) 34:1306–14. doi: 10.1038/jcbfm.2014.83

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yang, Yang, DeMars, Rosenberg and Candelario-Jalil. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.